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Silent brain infarction (SBI) is defined as an asymptomatic infarction, and is often
incidentally detected on computed tomography (CT) or magnetic resonance
imaging (MRI) in subjects with no history of stroke. It is relatively common in the
elderly, and the incidence of SBI significantly increases with older age.
1,2 The
presence of SBI has been identified as an independent risk factor for the
development of symptomatic infarction.
3-7 Therefore, population-based studies
have been performed to identify risk factors for SBI, as well as factors that
promote the progression of SBI to other symptomatic cerebrovascular disorders.
8
It has been suggested that hyperhomocysteinemia is a risk factor for a number of
occlusive vascular diseases, including SBI.
2,9-12 The methylenetetrahydrofolate
reductase (MTHFR) gene has genetic variants (677C>T and 1298A>C) that reduce
the enzyme activity, thereby elevating plasma total homocysteine (tHcy) levels.
13-17
Most previous studies have concentrated on the MTHFR 677C>T polymorphisms
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Purpose: Methylenetetrahydrofolate reductase (MTHFR) is the main regulatory enzyme for homocysteine
metabolism. In the present study, we evaluated whether the MTHFR 677C>T and 1298A>C gene polymorphisms
are associated with SBI and plasma homocysteine concentration in a Korean population. Materials and Methods:
We enrolled 264 patients with SBI and 234 healthy controls in South Korea. Fasting plasma total homocysteine
(tHcy) concentrations were measured, and genotype analysis of the MTHFR gene was carried out. Results: The
plasma tHcy levels were significantly higher in patients with SBI than in healthy controls. Despite a significant
association between the MTHFR 677TT genotype and hyperhomocysteinemia, the MTHFR 677C>T genotypes did
not appear to influence susceptibility to SBI. However, odds ratios of the 1298AC and 1298AC + CC genotypes for
the 1298AA genotype were significantly different between SBI patients and normal controls. The frequencies of
677C-1298A and 677C-1298C haplotypes were significantly higher in the SBI group than in the control group.
Conclusion: This study demonstrates that the MTHFR 1298A>C polymorphism is a risk factor for SBI in a
Korean population. The genotypes of 677C>T and 1298A>C polymorphisms interact additively, and increase the
risk of SBI in Korean subjects. 
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INTRODUCTIONassociated with stroke, cancer, birth defects, recurrent abor-
tion, and cardiovascular disorders.
15,18-24 However, only a few
studies have been conducted to assess the association of a
second common polymorphism, 1298A>C, with ischemic
stroke, cancer, and heart disease.
25-31 No association studies
of the MTHFR 1298A>C polymorphism with SBI were
conducted.
Therefore, we conducted this study to investigate the
association between the MTHFR 677C>T and 1298A>C
polymorphisms and the risk of SBI in a Korean population. 
Patients 
The study population was composed of 264 patients (121
males, 143 females; mean age ± SD, 62.26 ± 11.95 years)
with SBI and 227 control subjects (109 males, 118 females;
mean age ± SD, 59.62 ± 11.67 years). Patients with SBI
were enrolled and recruited between July 2000 and February
2005 in the Bundang CHA Hospital.
Patients with known history of stroke or cardiovascular
diseases were excluded. MRI was performed on a 1.5-T
superconducting magnet (Siemens Magnetom Symphony,
Erlangen, Germany). Transverse T1-weighted, T2-weight-
ed, and FLAIR images were obtained with a slice thickness
of 7 mm. The diagnosis of SBI was made as follows: 1)
spotty areas ≥3 mm in diameter in the area supplied by deep
perforating arteries, showing high intensity in the T2 and
FLAIR images and low intensity in the T1 image; 2) ab-
sence of neurological signs and symptoms corresponding to
the MRI lesions; 3) no history of clinical stroke, including
transient ischemic attack. Small punctate hyperintensity
lesions (1 to 2 mm in diameter) were more likely to repre-
sent a dilated perivascular space, and were not considered in
the present study. The diagnosis of SBI was made when two
independent researchers agreed on the diagnosis. 
Controls (n = 227), which showed no evidence of SBI
on MRI, were recruited from subjects who visited the
hospital for a health examination. They had no past history
of stroke or cardiovascular disease. Our subjects were clas-
sified into two age groups: subjects aged < 65 years and
subjects aged ≥ 65 years. Baseline demographic data and a
history of conventional vascular risk factors were obtained
from each control subject. Detailed information on medical
history was obtained from all study subjects. The institu-
tional review committee of Bundang CHA Hospital appro-
ved this study in June 2000. Informed consent was obtained
from all participants.
Biochemical measurements 
Overnight fasting (12 hours) blood samples were collected
in EDTA-containing tubes and immediately placed on ice.
After centrifugation at 2000 rpm for 15 minutes, plasma
samples were kept at -20˚C until analysis. Plasma total
homocysteine (tHcy) levels were determined by fluores-
cence polarization immunoassay (IMx, Abbott Laboratories,
North Chicago, IL, USA).
Genetic analysis  
Genomic DNA was extracted from leukocytes by using a
DNA extraction kit (QIAmp blood kit, Qiagen) according
to the protocol of the manufacturer. MTHFR 677C>T and
1,298A>C genotypes were identified as described previou-
sly.
15,17 Regions containing the two polymorphisms were
amplified separately. For the nucleotide 677 polymorphi-
sm, the primers 5’-GCA CTT GAA GAG AAG GTG TC-
3’ (forward) and 5’-AGG ACG GTG CGG TGA GAG TG-
3’ (reverse) were used, and for the nucleotide 1298 poly-
morphism, 5’-CTT TGG GGA GCT GAA GGA CTACTA
C-3’ (forward) and 5’-CAC TTT GTG ACC ATT CCG
GTT TG-3’ (reverse) were used. Human genomic DNA
(200 ng) was amplified with 100 pmol of each forward and
reverse primer, 1.5 mM MgCl2, 0.2 M each deoxynucleo-
tide triphosphate, and 1 unit Taq polymerase (Takara,
Madison, Wisconsin, USA) in a total volume of 100 uL.
PCR conditions were as follows: denaturation at 94˚C for 5
min, followed by 35 cycles at 94˚C for 30s, 51˚C for 30s,
and 72˚C for 30s, and a final terminal elongation at 72˚C for
5 min. PCR products were digested with HinfI (for nucleo-
tide 677) or Fnu4HI (for nucleotide 1,298) for 2 hours at
37˚C. 
Amplification success was monitored by 3.0% agarose
electrophoresis. For the nucleotide 677, an undigested
PCR product (203 bp) indicated a homozygous wild-type,
three bands of 203, 173, and 30 bp indicated the heterozy-
gous genotype, and two bands of 170 and 30 bp indicated
the homozygous genotype. For nucleotide 1,298, a single
band of 138 bp indicated a wild-type, and two fragments
of 119 and 19 bp indicated the homozygous genotype.
Statistical analysis 
To estimate the relative risk for SBI for the various geno-
types, an odds ratio (OR) and 95% confidence interval (CI)
were calculated. Differences between the patient and
control groups were assessed by the χ 2 test for categorical
variables (sex, hypertension, and diabetes mellitus) and the
two-sample t-test for continuous variables (age and tHcy
level). For the multivariate analysis, logistic regression an-
alysis was used to adjust for possible confounders, including
age, sex, hypertension, and diabetes mellitus. The plasma
tHcy levels differences between patients and controls were
examined by analysis of covariance (ANCOVA), adjusted
for age and sex. Haplotypes analysis was performed using
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case-control haplotype analysis-permutation test. 
The analysis was performed using GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA, USA), Stats-
Direct Statistical Software Version 2.4.4 (StatsDirect Ltd.,
Altrincham, UK), Medcalc (version 7.4 for Windows;
Frank. Schoonjans, Belgium) and SAS 9.1 for Windows
(SAS Institute Inc., Cary, NC, USA).
Table 1 shows the distributions of clinical characteristics
of patients with SBI and control subjects. Patients had a
significantly higher prevalence of hyperlipidemia, but not
of diabetes mellitus or hypertension, compared to the con-
trols. To evaluate the pure effects of the MTHFR genotypes
on SBI, we adjusted the OR for age, sex, hypertension, and
diabetes mellitus. Significant elevation of pHcy concen-
trations was found in patients compared to controls (11.34
± 6.385 µmol/L vs. 9.676 ± 3.959 µmol/L, p= 0.0007). 
In this study, all of the study populations were in Hardy-
Weinberg equilibrium. The 1298AC genotype was found
to show a significant 1.734-fold increased risk of develop-
ing SBI (AOR = 1.734, 95% CI = 1.13-2.66), and 1298AC
+ CC genotypes were significantly associated with a 1.825-
fold increased risk for SBI (AOR = 1.825, 95% CI = 1.20-
2.78), whereas for the MTHFR 677C>T polymorphisms in
SBI patients there were no statistically significant
differences in the effects of the MTHFR genotypes on SBI
between the patients and the controls (Table 2). 
For the MTHFR 1298A>C polymorphisms, significant
difference was found in terms of the risk for SBI in females
RESULTS
Table 1. Baseline Characteristics in Silent Brain Infarction (SBI) Patients and Control Subjects
Control (%) SBI (%) p value
Male (%) 116 (49.6) 121 (45.8) 0.420
Age (yrs)* 59.55  ± 11.75 62.38  ± 11.90 0.008
tHcy (µmol/L)* 9.68  ± 3.96 11.34  ± 6.39 0.001
Folate (nmol/L)* 9.85  ± 6.61 9.70  ± 5.99 0.845
Hypertension  118 (50.6) 141 (53.4) 0.598
Diabetes mellitus  42 (18.1) 38 (14.4) 0.273
Hyperlipidemia  43 (18.4) 86 (32.8) 0.0003
p-values are Chi-square test for categorical data, and two sample t-test for the continuous data.
*Values are mean ±SD (standard deviation). 
Table 2. Comparison of Genotype Frequencies in the MTHFR 677C>T and 1298A>C Polymorphisms between
Patients with Silent Brain Infarction (SBI) and Control Subjects
Genotype Controls (%) Cases (%) AOR (95% CI)
MTHFR 677
CC 71 (30.3) 75 (28.5) 1.0 (-)
CT 128 (54.7) 139 (52.9) 1.118 (0.74 - 1.70)
TT 35 (15.0) 49 (18.6) 1.380 (0.78 - 2.44)
CT+TT 163 (69.7) 188 (71.5) 1.168 (0.78 - 1.74)
MTHFR 1298
AA 182 (77.8) 179 (67.8) 1.0 (-)
AC 51 (21.8) 80 (30.3) 1.734 (1.13 - 2.66)
CC 1 (0.4) 5 (1.9) 6.489 (0.73 - 57.95)
AC+CC 52 (22.2) 85 (32.2) 1.825 (1.20 - 2.78)
MTHFR 677 / 1298
CC / AA 50 (21.4) 33 (12.5) 1.0 (-)
CC / AC 20 (8.5) 37 (14.2) 2.689 (1.26 - 5.76)
CC / CC 1 (0.4) 5 (1.9) 9.451 (0.95 - 94.14)
CT / AA 97 (41.5) 96 (36.5) 1.611 (0.94 - 2.77)
CT / AC 31 (13.2) 43 (16.3) 2.604 (1.29 - 5.25)
TT / AA 35 (15.0) 49 (18.6) 2.289 (1.19 - 4.42)
AOR, adjusted odds ratios (adjusted by age, gender, hypertension, diabetes mellitus, and hyperlipidemia); MTHFR, methylenetetrahydrofolate
reductase.In Bo Han, et al.
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(AC, AOR = 2.205, 95% CI = 1.11-3.70; AC + CC, AOR =
2.106, 95% CI = 1.16-3.83). When this population was
separated into two age groups, 1298AC + CC genotypes
showed a 1.789-fold increased risk for SBI in patients aged
< 65 years, and this relationship showed statistical signi-
ficance (AOR = 1.789; 95% CI = 1.05-3.05) (Table 3). In
addition, when stratified by age of 55 years, genotype
frequencies were significantly different for SBI in females
and older than 55 years (in females, AC, AOR = 2.025,
95% CI = 1.11-3.70, AC + CC, AOR = 2.106, 95% CI =
1.16-3.83; in ≥ 55 years, AC, AOR = 1.987, 95% CI =
1.18-3.34, AC + CC, AOR = 2.088, 95% CI = 1.25-3.50).
MTHFR 677C>T polymorphism in subgroup analysis of
the SBI patients was not statistically significant such as
genders or age groups (p> 0.05; data not shown).
As seen in Table 2, nine combinations are possible.
However, no individual with 677CT/1298CC, 677TT/
1298AC, and 677TT/1298CC was detected.
32-34 The
compound genotype of 677CC/1298AC showed a 2.689-
fold increased risk for SBI (AOR=2.689, 95% CI = 1.26-
5.76), and the compound genotype of 677CT/1298AC
revealed a 2.604-fold increased risk for SBI (AOR = 2.604,
95% CI = 1.29-5.25). The 677TT/1298AA compound
genotype was approximately 2.3 times more prone to
developing SBI than the controls (AOR = 2.289; 95% CI =
1.19-4.42) (Table 2). 
Four haplotypes are possible, but the 677T-1298C
haplotype was not present in our patient population. When
the cases of SBI were compared with the controls, there
were significant differences in the distribution frequency
between cases and controls for the 677C-1298A (p =
0.006) and 677C-1298C (p = 0.009) haplotypes (Table 4).
The 677C-1298A haplotype showed a lower frequency in
patients with SBI than in the controls. However, the 677C-
1298C haplotype was more frequently observed in patients
than in controls. 
The tHcy levels were higher in patients with heterozy-
gous 677CT and 677CT + TT genotypes compared to the
corresponding control population. A statistically significant
elevation of tHcy levels was observed for genotypes
Table 3. Comparison of Genotype Frequencies in the MTHFR 1298A>C Polymorphism between Patients 
with Silent Brain Infarction (SBI) and Control Subjects, Stratified by Sex and Age
MTHFR 1298 Controls (%) Cases (%) AOR (95% CI)
AA 182 (77.8) 179 (67.8) 1.0 (-)
AC 51 (21.8) 80 (30.3) 1.734 (1.13 - 2.66)*
CC 1 (0.4) 5 (1.9) 6.489 (0.73 - 57.95)
AC + CC 52 (22.2) 85 (32.2) 1.825 (1.20 - 2.78)*
Male
AA 92 (79.3) 85 (70.2)
AC 24 (20.7) 33 (27.3) 1.638 (0.87 - 3.08)
CC 0 (0.0) 3 (2.5) -
AC + CC 24 (20.7) 36 (29.8) 1.784 (0.96 - 3.32)
Female
AA 90 (76.3) 94 (65.7)
AC 27 (22.9) 47 (32.9) 2.025 (1.11 - 3.70)*
CC 1 (0.8) 2 (1.4) 5.176 (0.43 - 62.71)
AC + CC 28 (23.7) 49 (34.3) 2.106 (1.16 - 3.83)*
≥65 yr
AA 70 (82.4) 85 (70.3)
AC 15 (17.6) 35 (28.9) 1.803 (0.89 - 3.64)
CC 0 (0.0) 1 (0.8) -
AC + CC 15 (17.6) 36 (29.7) 1.848 (0.92 - 3.73)
< 65 yr
AA 112 (75.2) 94 (65.7)
AC 36 (24.2) 45 (31.5) 1.665 (0.97 - 2.87)
CC 1 (0.6) 4 (2.8) 6.213 (0.67 - 57.86)
AC + CC 37 (24.8) 49 (34.3) 1.789 (1.05 - 3.05)*
AOR, adjusted odds ratios (adjusted by age, gender, hypertension, diabetes mellitus and hyperlipidemia); MTHFR, methylenetetrahydrofolate 
reductase. 
*p  < 0.05.1298AA, 1298AC, and 1298AC + CC. The tHcy levels
were higher in patients with 1298CC than in the controls,
but did not reach statistical significance due to the limited
number of cases with this genotype. In combined geno-
types, the tHcy levels were significantly higher in patients
with 677CT/1298AC than in the controls, and 677TT/
1298AA genotypes showed an increase in tHcy levels
compared to controls, with marginal significance (Table 5).
Hyperhomocysteinemia is a well-known risk factor for
vascular diseases, including stroke, and it has been sug-
gested that this condition may be a risk factor for the
development of SBI.
8,9,12 The tHcy levels can potentially be
elevated by either environmental (including diet) and/or
genetic factors. 
The common polymorphism in the MTHFR 677C>T
can reduce enzyme activity, resulting in hyperhomocystei-
nemia, and can also increase the risks of cardiovascular
diseases, certain types of cancer, and birth defects.
31 The
MTHFR 1298A>C polymorphism has also been found to
reduce MTHFR enzyme activity, to a lesser extent than
those with the 677C>T mutation, but conflicting results
have been reported with respect to the association between
1298A>C polymorphism and tHcy levels. It has been
reported that the MTHFR 1298A>C polymorphism may
be associated with ischemic stroke, and may also play a
protective role against colorectal cancer and acute lympho-
cytic leukemia.
35
In this study, the tHcy levels were significantly higher in
patients with MTHFR 677TT than in patients with other
MTHFR 677C>T genotypes, while no correlation between
MTHFR Polymorphism and SBI Risk
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Table 5. Levels of Plasma Total Homocysteine According to MTHFR 677C>T and 1298A>C Genotypes in SBI 
Patients and Control Subjects
Controls (µmol/L)* Cases (µmol/L)* p value
Total 9.75  ± 0.347 11.28  ± 0.325 0.001 
MTHFR 677C>T
CC 9.32  ± 0.000 10.09  ± 0.365 0.147 
CT 9.67  ± 0.367 10.76  ± 0.351 0.034 
TT 10.69  ± 1.581 14.69  ± 1.316 0.056 
CT + TT 9.95  ± 0.466 11.75  ± 0.432 0.005 
MTHFR 1298A>C
AA 9.99  ± 0.435 11.81  ± 0.439 0.004 
AC 8.84  ± 0.450 10.17  ± 0.349 0.022 
CC 12.79  ± 3.289 9.36  ± 1.216 0.456 
AC + CC 8.87  ± 0.440 10.16  ± 0.334 0.022 
MTHFR 677 / 1298
CC / AA 9.34  ± 0.416 9.74  ± 0.514 0.554 
CC / AC 9.34  ± 0.824 10.37  ± 0.593 0.320 
CC / CC 12.79  ± 3.288 9.37  ± 1.216 0.456 
CT / AA 10.04  ± 6.335 11.10  ± 6.336 0.107 
CT / AC 8.49  ± 2.825 10.02  ± 2.809 0.027 
TT / AA 10.69  ± 9.339 14.69  ± 9.298 0.056 
MTHFR, methylenetetrahydrofolate reductase.
*Mean ±standard error. 
pvalues are calculated by an analysis of covariance (ANCOVA). Homocysteine levels are adjusted by age and gender.
DISCUSSION
Table 4. Comparison of Haplotype Frequencies in the MTHFR 677C>T and 1298A>C Polymorphisms 
between Patients with Silent Brain Infarction (SBI) and Control Subjects 
Haplotype Overall Controls Cases p value
T-A 0.438 0.423 0.451 0.383
C-A 0.419 0.464 0.378 0.006
C-C 0.144 0.113 0.171 0.009
MTHFR, methylenetetrahydrofolate reductase.
p-values are calculated by the permutation test. tHcy and MTHFR 1298A>C genotypes was found. Recent
studies have demonstrated that 1298A>C, in combination
with 677C>T, may be associated with decreased MTHFR
activity resulting in hyperhomocysteinemia, which is con-
sistent with our results (Table 5).
14,36-38 MTHFR 1298AC
and MTHFR 1298AC + CC individuals were more prone to
an increased risk for SBI than the corresponding controls,
while the polymorphism of 677C>T at the MTHFR gene
did not significantly influence the risk of SBI. When com-
bined with the 1298A>C genotypes, however, we found
that MTHFR 677C>T could have an additive effect on the
variation at the MTHFR 1298A>C gene, because indi-
viduals carrying the predisposing variants (677CC/1298AC,
677CT/1298AC, 677TT/1298AA) at the two loci showed
a higher risk of the development of SBI than any AOR
individuals registered for MTHFR 1298A>C genotypes
(Table 2).
Furthermore, we investigated the associations between
SBI and allele haplotypes. The C-C haplotype increased
the risk of SBI, whereas the C-A haplotype, a normal allele-
combined haplotype, decreased the risk of the develop-
ment of SBI. These results suggested that 1298A>C may
be a more important genetic risk factor for SBI than
677C>T, and the MTHFR 1298C allele-containing haplo-
type may have the potential to be a predictive marker of
the development of SBI in the Korean population.
However, the relationships between MTHFR poly-
morphisms and multifactorial diseases, especially cardio-
vascular disease and stroke, remain highly controversial,
and genetic influences of MTHFR polymorphisms have
not been observed in a number of populations. There was a
racial difference in the frequency of the 1298C allele:
Canadian, 0.36, French, 0.33, English, 0.32, German, 0.30,
American, 0.29, South African, 0.21, Japanese, 0.19,
Chinese, 0.17, Korean, 0.125, Korean, 0.178, and Korean,
0.163.
25,28,32,36,37,39-42 From the literature, the MTHFR 1298C
allele frequency was 0.125 to 0.178 in the Korean popula-
tions. The 1298CC genotype is present at a much lower
frequency, at 1.4-3.7%, in Asian populations, compared to
7.2-12.6% in the Caucasian population; this information is
consistent with our results.
25,27-29,32,36,39 In the current study,
the frequencies of the 1298AA, AC, and CC genotypes in
the control group were 77.8%, 21.8%, and 0.4%, respecti-
vely. The corresponding frequencies in the patient group
were 67.8%, 30.3%, and 1.9%, respectively. The frequency
of the MTHFR 1298C allele was significantly higher in the
SBI patients than in the controls. These findings indicate
that there are ethnic variations in terms of the 1298A>C
polymorphism, as well as a difference in the occurrence of
SBI between the Asian population and the Caucasian pop-
ulation. It is conceivable that the contributions of MTHFR
polymorphisms to SBI may vary in different ethnic groups.
In addition, no statistically significant difference in the
risk for SBI was found between MTHFR genotypes in
subjects over 65 years of age. We found that the 1298AC
and 1298AC + CC genotypes showed an increased risk for
SBI in patients under 65 years of age. SBI, a cerebrovascular
disease, has an age-dependent nature. The causes of SBI
are multifactorial, and additional environmental risk factors
of SBI may develop with age. In this study, logistic regres-
sion, adjusting for possible confounders such as age,
hypertension, and diabetes mellitus, showed a significant
relationship between the 1298A>C polymorphism and
early-onset SBI under 65 years of age. Prior to this study,
Kohara, et al.
2 reported that the MTHFR 677TT genotype
is an independent risk factor for SBI and white matter
lesions in the general Japanese population, especially in
elderly subjects over 60 years of age. Since genetic poly-
morphisms often vary among ethnic groups or geographical
areas, further studies are needed to clarify the association
between MTHFR polymorphisms and SBI in diverse
ethnic populations.
This study has limitations because it was conducted in a
hospital-based population. The other possible limitations
are related to exposure to different environmental factors,
such as daily folate intake, additional genetic effects such
as methionine synthase (MTR) and methionine synthase
reductase (MTRR), and ethnic differences. Large, com-
munity-based random sampling is needed in order to resolve
these limitations.
Despite these limitations, this study is unique in that it
focused on the relationship between the MTHFR 1298A>C
polymorphism and SBI in a Korean population. This study
presents evidence that the 1298A>C polymorphism, but not
the 677C>T polymorphism, acts as an independent risk
factor for SBI, especially in patients under 65 years of age.
In addition, it indicates that the polymorphisms of MTHFR
677C>T and 1298A>C interact additively, resulting in an
increased risk of SBI in a Korean population. 
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